A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Ferlay, J.; Steliarova-Foucher, E.; Lortet-Tieulent, J.; Rosso, S.; Coebergh, J.; Comber, H.; Forman, D.; Bray, F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur. J. Cancer 2013, 49, 1374–1403. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, Y.-L.; Yuan, J.-Q.; Wang, K.-F.; Fu, X.-H.; Han, X.-R.; Threapleton, D.; Yang, Z.-Y.; Mao, C.; Tang, J.-L. The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget 2016, 7, 78985–78993. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oxnard, G.R.; Miller, V.A.; Robson, M.E.; Azzoli, C.G.; Pao, W.; Ladanyi, M.; Arcila, M.E. Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping. J. Thorac. Oncol. 2012, 7, 1049–1052. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rosell, R.; Carcereny, E.; Gervais, R.; Vergnenègre, A.; Massuti, B.; Felip, E.; Palmero, R.; Garcia-Gomez, R.; Pallares, C.; Sanchez, J.M.; et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012, 13, 239–246. [Google Scholar] [CrossRef]
- Mok, T.S.-K.; Wu, Y.-L.; Thongprasert, S.; Yang, J.C.; Chu, D.-T.; Saijo, N.; Sunpaweravong, P.; Han, B.; Margono, B.; Ichinose, Y.; et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. New Engl. J. Med. 2009, 361, 947–957. [Google Scholar] [CrossRef]
- Sequist, L.V.; Yang, J.C.; Yamamoto, N.; O’Byrne, K.; Hirsh, V.; Mok, T.S.-K.; Geater, S.L.; Orlov, S.V.; Tsai, C.-M.; Boyer, M.; et al. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. J. Clin. Oncol. 2013, 31, 3327–3334. [Google Scholar] [CrossRef] [Green Version]
- Mok, T.S.; Wu, Y.-L.; Ahn, M.-J.; Garassino, M.C.; Kim, H.R.; Ramalingam, S.S.; Shepherd, F.A.; He, Y.; Akamatsu, H.; Theelen, W.S.; et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N. Engl. J. Med. 2016, 376, 629–640. [Google Scholar] [CrossRef] [Green Version]
- Soria, J.-C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K.H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T.; et al. Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer. New Engl. J. Med. 2018, 378, 113–125. [Google Scholar] [CrossRef]
- Planchard, D.; Popat, S.; Kerr, K.; Novello, S.; Smit, E.; Faivre-Finn, C.; Mok, T.S.-K.; Reck, M.; Van Schil, P.; Hellmann, M.; et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2018, 29, iv192–iv237. [Google Scholar] [CrossRef]
- Rolfo, C.; Mack, P.C.; Scagliotti, G.V.; Baas, P.; Barlesi, F.; Bivona, T.G.; Herbst, R.S.; Mok, T.S.; Peled, N.; Pirker, R.; et al. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. J. Thorac. Oncol. 2018, 13, 1248–1268. [Google Scholar] [CrossRef] [Green Version]
- Lindeman, N.I.; Cagle, P.T.; Aisner, D.L.; Arcila, M.E.; Beasley, M.B.; Bernicker, E.H.; Colasacco, C.; Dacic, S.; Hirsch, F.R.; Kerr, K.; et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. J. Thorac. Oncol. 2018, 13, 323–358. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Offin, M.; Chabon, J.J.; Razavi, P.; Isbell, J.M.; Rudin, C.M.; Diehn, M.; Li, B.T. Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA. J. Oncol. 2017, 2017, 4517834. [Google Scholar] [CrossRef] [PubMed]
- Jamal-Hanjani, M.; Wilson, G.A.; McGranahan, N.; Birkbak, N.J.; Watkins, T.B.; Veeriah, S.; Shafi, S.; Johnson, D.H.; Mitter, R.; Rosenthal, R.; et al. Tracking the Evolution of Non-Small-Cell Lung Cancer. New Engl. J. Med. 2017, 376, 2109–2121. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mok, T.S.-K.; Wu, Y.-L.; Lee, J.S.; Yu, C.-J.; Sriuranpong, V.; Sandoval-Tan, J.; Ladrera, G.; Thongprasert, S.; Srimuninnimit, V.; Liao, M.; et al. Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Clin. Cancer Res. 2015, 21, 3196–3203. [Google Scholar] [CrossRef] [Green Version]
- Oxnard, G.; Paweletz, C.P.; Kuang, Y.; Mach, S.L.; O’Connell, A.; Messineo, M.M.; Luke, J.J.; Butaney, M.; Kirschmeier, P.; Jackman, D.M.; et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res. 2014, 20, 1698–1705. [Google Scholar] [CrossRef] [Green Version]
- Li, Z.; Zhang, Y.; Bao, W.; Jiang, C. Insufficiency of peripheral blood as a substitute tissue for detecting EGFR mutations in lung cancer: A meta-analysis. Target. Oncol. 2014, 9, 381–388. [Google Scholar] [CrossRef]
- Oxnard, G.; Thress, K.S.; Alden, R.S.; Lawrance, R.; Paweletz, C.P.; Cantarini, M.; Yang, J.C.-H.; Barrett, J.C.; Jänne, P.A. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer. J. Clin. Oncol. 2016, 34, 3375–3382. [Google Scholar] [CrossRef] [Green Version]
- Test Molecolari Biopsia Liquida Oncologia. 2018. Available online: https://www.aiom.it/raccomandazioni-per-lesecuzione-di-test-molecolari-su-biopsia-liquida-in-oncologia-luglio-2018/ (accessed on 9 July 2020).
- Saarenheimo, J.; Eigeliene, N.; Andersén, H.; Tiirola, M.; Jekunen, A. The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer. Front. Oncol. 2019, 9, 129. [Google Scholar] [CrossRef] [Green Version]
- Yang, J.C.; Ahn, M.-J.; Kim, D.-W.; Ramalingam, S.S.; Sequist, L.V.; Su, W.-C.; Kim, S.W.; Kim, J.-H.; Planchard, D.; Felip, E.; et al. Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J. Clin. Oncol. 2017, 35, 1288–1296. [Google Scholar] [CrossRef]
- Minari, R.; Mazzaschi, G.; Bordi, P.; Gnetti, L.; Alberti, G.; Altimari, A.; Gruppioni, E.; Sperandi, F.; Parisi, C.; Guaitoli, G.; et al. Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study. Clin. Lung Cancer 2020. [Google Scholar] [CrossRef]
- Mondaca, S.P.; Offin, M.; Borsu, L.; Myers, M.; Josyula, S.; Makhnin, A.; Shen, R.; Riely, G.J.; Rudin, C.M.; Ladanyi, M.; et al. Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers. Acta Oncol. 2019, 58, 1634–1639. [Google Scholar] [CrossRef] [PubMed]
- Del Re, M.; Petrini, I.; Mazzoni, F.; Valleggi, S.; Gianfilippo, G.; Pozzessere, D.; Chella, A.; Crucitta, S.; Rofi, E.; Restante, G.; et al. Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. Clin. Lung Cancer 2020, 21, 232–237. [Google Scholar] [CrossRef] [PubMed]
- Buder, A.; Setinek, U.; Hochmair, M.J.; Schwab, S.; Kirchbacher, K.; Keck, A.; Burghuber, O.C.; Pirker, R.; Filipits, M. EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR. Target. Oncol. 2019, 14, 197–203. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Spence, T.; Perera, S.; Weiss, J.; Grenier, S.; Ranich, L.; Shepherd, F.; Stockley, T. Clinical implementation of circulating tumour DNA testing for EGFR T790M for detection of treatment resistance in non-small cell lung cancer. J. Clin. Pathol. 2020. [Google Scholar] [CrossRef]
- Passiglia, F.; Rizzo, S.; Di Maio, M.; Galvano, A.; Badalamenti, G.; Listì, A.; Gulotta, L.; Castiglia, M.; Fulfaro, F.; Bazan, V.; et al. The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: A systematic review and meta-analysis. Sci. Rep. 2018, 8, 13379. [Google Scholar] [CrossRef] [Green Version]
- Maso, A.D.; Lorenzi, M.; Roca, E.; Pilotto, S.; Macerelli, M.; Polo, V.; Cecere, F.L.; Del Conte, A.; Nardo, G.; Buoro, V.; et al. Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. Clin. Lung Cancer 2020, 21, 1–14. [Google Scholar] [CrossRef] [Green Version]
- Aldea, M.; Hendriks, L.; Mezquita, L.; Jovelet, C.; Planchard, D.; Auclin, E.; Remon, J.; Howarth, K.; Benitez, J.C.; Gazzah, A.; et al. Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression. J. Thorac. Oncol. 2020, 15, 383–391. [Google Scholar] [CrossRef]
- Lettig, L.; Sahnane, N.; Pepe, F.; Cerutti, R.; Albeni, C.; Franzi, F.; Veronesi, G.; Ogliari, F.; Pastore, A.; Tuzi, A.; et al. EGFR T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencing. Transl. Lung Cancer Res. 2019, 8, 584–592. [Google Scholar] [CrossRef]
- Smeltzer, M.P.; Wynes, M.W.; Lantuejoul, S.; Soo, R.; Ramalingam, S.S.; Varella-Garcia, M.; Taylor, M.M.; Richeimer, K.; Wood, K.; Howell, K.E.; et al. The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer. J. Thorac. Oncol. 2020. [Google Scholar] [CrossRef]
Year | Overall | 2017 | 2018 |
---|---|---|---|
Pts. tested (overall) | 475 | 159 | 316 |
LB (overall) | 654 | 298 | 356 |
At diagnosis | |||
Pts tested | 192 | 84 | 108 |
LB performed | 192 | 84 | 108 |
% of EGFR mutation | 16% | 18% | 15% |
At PD | |||
Pts tested | 283 | 75 | 208 |
LB performed | 462 | 214 | 248 |
LB/pts ratio | 1.63 | 2.88 | 1.2 |
% of pts T790M+ | 35% | 61% | 26% |
% of LB T790M+ | 22% | 21% | 22% |
% of LB Act+/T790M− | 34% | 33% | 35% |
% of LB Act−/T790M− | 44% | 45% | 43% |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Cortiula, F.; Pasello, G.; Follador, A.; Nardo, G.; Polo, V.; Scquizzato, E.; Del Conte, A.; Miorin, M.; Giovanis, P.; D’Urso, A.; et al. A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients. Diagnostics 2020, 10, 765. https://doi.org/10.3390/diagnostics10100765
Cortiula F, Pasello G, Follador A, Nardo G, Polo V, Scquizzato E, Del Conte A, Miorin M, Giovanis P, D’Urso A, et al. A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients. Diagnostics. 2020; 10(10):765. https://doi.org/10.3390/diagnostics10100765
Chicago/Turabian StyleCortiula, Francesco, Giulia Pasello, Alessandro Follador, Giorgia Nardo, Valentina Polo, Elisa Scquizzato, Alessandro Del Conte, Marta Miorin, Petros Giovanis, Alessandra D’Urso, and et al. 2020. "A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients" Diagnostics 10, no. 10: 765. https://doi.org/10.3390/diagnostics10100765